Option chain shows key data for Onconetix's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Onconetix.

Onconetix (NASDAQ:ONCO) Stock, Option Chain

Onconetix

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

eye-5248678

News

ONCO

Onconetix shares are trading higher by 85% during Tuesday&#39;s session. The company signed a non-binding letter of intent to merge with privately held Ocuvex Therapeutics.

Why Onconetix (ONCO) Stock Is Exploding Higher

Recent Gains

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

PXLW

RMBI

TVGN

VINC

Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket

wall street chart shutter2

Equities

Eurozone

Commodities

Intraday Update

ACAD

COCP

SGMO

Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide

Onconetix Inc

ONCO-INNOVATIONS LTD by ONCO-INNOVATIONS LTD.

ONCOPEPTIDES AB AK by ONCOPEPTIDES AB

OncoCyte Corp

ONCOSEC MEDICAL INC NEW by OncoSec Medical Incorporated

OncoSec Medical Inc

OncoSil Medical Ltd

ONCOVISTA INNVTVE THERPS by OncoVista Innovative Therapies, Inc.

OncoVista Innovative Therapies Inc

ONCOLOGIX TECH INC by Oncologix Tech, Inc.

Oncologix Tech Inc

ONCOLOGY PHARMA INC by Oncology Pharma Inc.

Oncology Pharma Inc

Oncolytics Biotech Inc

Oncorus Inc rdinary Shares

ONCOTELIC THERAPEUTCS INC by Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc

Press Releases

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress

Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort

Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

ENTO

VRNA

Aditxt

Alzamend Neuro

Aptevo Therapeutics

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Entero Therapeutics

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

NuCana

Oragenics

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Plus Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

Comments

Onconetix

Onconetix (ONCO) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell